Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Satoh

Showing results (1241-1250 of 1,245) with videos related to

Pageof 125
Sort By:
You have reached the last page of results.This site can display upto 1,245 results.
ESMO Open|February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2S Stintzing, J Tabernero, T Satoh, et al.
Journal of Cancer Research and Clinical Oncology|February 18, 2017
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancerTakuji Okusaka, H Miyakawa, H Fujii, et al.
The Japanese Journal of Antibiotics|August 1, 1981
[Clinical evaluation of cefotiam in internal medicine, with special reference to infectious disease associated with hematological disorders (author's transl)]T Uchida, S Matsuda, T Tanaka, et al.
ESMO Open|October 10, 2025
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)T Masuishi, H Taniguchi, D Kotani, et al.
Investigational New Drugs|April 30, 2015
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studiesA Omlin, R J Jones, R van der Noll, et al.
Pageof 125

Showing results (1241-1250 of 1,245) with videos related to

Sort By:
Pageof 125
You have reached the last page of results.This site can display upto 1,245 results.
ESMO Open|February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2S Stintzing, J Tabernero, T Satoh, et al.
Journal of Cancer Research and Clinical Oncology|February 18, 2017
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancerTakuji Okusaka, H Miyakawa, H Fujii, et al.
The Japanese Journal of Antibiotics|August 1, 1981
[Clinical evaluation of cefotiam in internal medicine, with special reference to infectious disease associated with hematological disorders (author's transl)]T Uchida, S Matsuda, T Tanaka, et al.
ESMO Open|October 10, 2025
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)T Masuishi, H Taniguchi, D Kotani, et al.
Investigational New Drugs|April 30, 2015
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studiesA Omlin, R J Jones, R van der Noll, et al.
Pageof 125